Opthea
Suite 0403, Level 4, 650 Chapel Street
South Yarra
Victoria
3141
Tel: 613-9826-0399
Website: http://www.opthea.com/
Email: info@opthea.com
93 articles about Opthea
-
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
3/19/2024
Opthea Limited announced it will host a virtual key opinion leader event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts:
-
Opthea to Participate in the Leerink Partners Global Biopharma Conference
3/5/2024
Opthea Limited announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
-
Opthea Reports Half-Year Financial Results and Business Updates
2/28/2024
Opthea Limited announced financial results for the six months ended December 31, 2023 and highlighted recent corporate and clinical updates.
-
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
2/19/2024
Opthea Limited, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor.
-
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
2/14/2024
Opthea Limited announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept -C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration.
-
Opthea Strengthens Team with Key Clinical and Regulatory Hires
2/1/2024
Opthea Limited announced the appointment of Julie Clark, MD, MS, as Senior Vice President, Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024.
-
Opthea to Receive US$35M Commitment and Additional US$50M Funding
12/27/2023
Opthea Limited announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.
-
Opthea Receives A$8.8 million R&D Tax Incentive
12/19/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received an A$8.8 million research and development tax credit from the Australian Taxation Office.
-
Opthea to Present at the FLORetina 2023 Congress
12/1/2023
Opthea Limited announced an oral presentation featuring sozinibercept which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
-
Opthea to Present at the Jefferies 2023 London Healthcare Conference
11/9/2023
Opthea Limited announced that Dr. Megan Baldwin, the Company’s Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023.
-
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
10/30/2023
Opthea Limited announced that Dr. Megan Baldwin, the Company’s Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023.
-
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
10/27/2023
Opthea Limited announced that the company’s Chief Executive Officer, Dr. Megan Baldwin, will transition to Founder and Chief Innovation Officer, reflective of the company’s strategy to advance its US and global presence and commercialization strategy for sozinibercept.
-
Opthea to Participate at the 2023 Euretina Congress
10/2/2023
Opthea Limited announced that on October 4th, Dr. Megan Baldwin, the Company’s Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization’s 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherlands.
-
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/7/2023
Opthea Limited announced that Mr. Tim Morris, the Company’s Chief Financial Officer will present at H.C. Wainwright’s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.
-
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
8/28/2023
Opthea Limited is pleased to announce the successful completion of the institutional component of the capital raising announced on Thursday, 24 August 2023.
-
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
7/26/2023
Opthea Limited announced that the American Medical Association’s United States Adopted Names Council, in consultation with the World Health Organization’s International Nonproprietary Names Expert Committee, has approved and adopted the nonproprietary drug name “sozinibercept” for the Company’s lead biologic drug candidate, OPT-302.
-
Opthea to Present at the 2023 Ophthalmology Innovation Summit
7/24/2023
Opthea Limited announced that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the 2023 Opthalmology Innovation Summit being held in Seattle, WA on July 27th, 2023.
-
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
7/13/2023
Opthea Limited announced that OPT-302, the Company’s first-in-class VEGF-C/D “trap” inhibitor will be highlighted during the upcoming American Society of Retina Specialists 2023 Annual Meeting in Seattle, Washington.
-
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
7/10/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced the resignation of Dr. Joel Naor, Chief Medical Officer, effective July 15th, 2023.
-
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
6/8/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company’s Board of Directors.